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Patients with resected stage II–III cutaneous melanomas remain at high risk for metastasis and death. Biomarker
development has been limited by the challenge of isolating high-quality RNA for transcriptome-wide profiling
from formalin-fixed and paraffin-embedded (FFPE) primary tumor specimens. Using NanoString technology, RNA
from 40 stage II–III FFPE primary melanomas was analyzed and a 53-immune-gene panel predictive of non-
progression (area under the curve (AUC)¼ 0.920) was defined. The signature predicted disease-specific survival
(DSS Po0.001) and recurrence-free survival (RFS Po0.001). CD2, the most differentially expressed gene in the
training set, also predicted non-progression (Po0.001). Using publicly available microarray data from 46 primary
human melanomas (GSE15605), a coexpression module enriched for the 53-gene panel was then identified using
unbiased methods. A Bayesian network of signaling pathways based on this data identified driver genes. Finally,
the proposed 53-gene panel was confirmed in an independent test population of 48 patients (AUC¼ 0.787). The
gene signature was an independent predictor of non-progression (Po0.001), RFS (Po0.001), and DSS (P¼ 0.024) in
the test population. The identified driver genes are potential therapeutic targets, and the 53-gene panel should be
tested for clinical application using a larger data set annotated on the basis of prospectively gathered data.
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INTRODUCTION
Metastatic melanoma is a devastating illness, taking the
lives of over 48,000 people worldwide per year (Manolio
et al., 2013). Patients who have had a stage II or stage III
melanoma excised remain at high risk for progression and
death because micro-metastases may have spread to other
body sites before resection. Stage II and III patients face an
approximate 50% risk of death, as compared witho10% risk
for stage I disease and 490% risk for stage IV disease (Balch
et al., 2009).
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Critical prognostic features describing a primary melanoma
lesion include depth, ulceration, and mitotic rate, all included
in the American Joint Committee on Cancer staging system.
Stage II disease is defined as melanomas of at least 1.01 mm in
depth with ulceration or at least 2.01 mm in depth without
ulceration. The 2009 American Joint Committee on Cancer
guidelines also identified mitotic rate as an independent
predictor of survival that is more significant than depth in
melanomas under 1 mm. Patients are classified as stage III,
regardless of tumor depth, if they have any local lymph node
metastasis, cutaneous metastasis, and/or ‘‘satellite lesions’’
defined as microscopic foci of tumor separated from the
dominant mass indicating subclinical cutaneous metastasis
(Balch et al., 2001, 2009).
For patients diagnosed with stage II melanoma, the best test
available to further estimate risk is a sentinel lymph node
biopsy. Patients with subclinical nodal metastasis may be
upstaged to stage III if the node is positive (Morton et al.,
2006; Wong et al., 2012). Stage III disease, however, is highly
heterogeneous. Five-year survival ranges from 87% for stage III
patients with one nodal micro-metastasis and a primary lesion
less than 2 mm down to 36% for stage III patients with four or
more involved nodes (Balch et al., 2010). Patients with stage
IIC disease (negative sentinel node but primary lesion 4 mm or
greater or 2 mm with ulceration) have a 5-year survival of only
48% (Balch et al., 2009). Thus, a deep primary melanoma
confers a worse prognosis than a microscopic focus of
melanoma in the sentinel node, likely due to hematogenous
spread (Balch et al., 2009). There is a clear need for prognostic
tools for patients with resected stage II–III melanoma, both for
surveillance and for stratification for clinical trials of newer
adjuvant therapies such as anti-CTLA4 and anti-PD1.
Evidence shows that the phenomenon of immune surveil-
lance has a key role in human solid tumors (Bindea et al.,
2011; Fridman et al., 2011; Ott et al., 2013). Thus, the
immunoscore, a grading system whereby tumor-infiltrating
lymphocytes (TILs) are enumerated and classified through
staining for CD3 and CD8, is a proposed biomarker for
cancer progression (Ascierto et al., 2013). In primary mela-
noma, it has historically been known that the presence of TILs
confers a more favorable prognosis (Clemente et al., 1996;
Azimi et al., 2012). Two factors limit widespread clinical
application of TIL quantification. First, TIL quantification is
subject to observer variability (Busam et al., 2001). Second,
the majority of patients have ‘‘non-brisk’’ TILs, an intermediate
category that offers little prognostic information (Azimi et al.,
2012). A barrier to the development of molecular markers
beyond TILs has been the clinical standards requiring
formalin-fixed and paraffin-embedded (FFPE) specimens for
diagnosis of primary melanoma, which complicates isolation
of RNA for transcriptome-wide profiling (Bogunovic et al.,
2009). Whole-genome arrays performed in frozen tissues and,
more recently, in FFPE tissues, have characterized melanomas
across multiple stages as high or low risk, and differentially
expressed genes include immune genes (Winnepenninckx
et al., 2006; Harbst et al., 2012; Mann et al., 2013).
However, no prognostic immune biomarkers are currently
available and despite the critical role of the immune system in
melanoma progression, we do not have a practical way to
translate this concept into clinical application. To address this
need, we used NanoString technology to profile a targeted set
of 446 immune-related genes in primary melanoma tumors
(Fortina and Surrey, 2008). We report that expression levels of
a 53-gene panel (subset of the 446 genes screened) predict
non-progression and prolonged recurrence-free survival (RFS)
and disease-specific survival (DSS) in two independent patient
populations with resectable stage II–III melanoma. Our results
suggest that larger-scale prospective studies should be con-
ducted to define genomic immune biomarkers in primary
melanoma tumors.
RESULTS
Characterization of 446-gene panel enriched for immune
function in a training set of 40 stage II–III primary FFPE
melanomas
NanoString is the most reliable technology capable of robustly
quantitating RNA levels for hundreds of genes in FFPE tissues,
and we used it to assess transcription levels across a broad
range of immune- and/or melanoma-related genes. We iden-
tified 446 genes of interest for profiling in the melanoma
samples on the basis of a PubMed search of the literature
(schema Figure 1a; Supplementary Tables S1 and S2 online).
Clinical characteristics of the training set are shown in
Figure 1b. Pathology databases at Geisinger Medical Center
(GMC, Danville, PA) and the Icahn School of Medicine at
Mount Sinai (MSSM, New York, NY) were screened for
primary stage II and III melanoma tumors. Patients were
scored as ‘‘progressors’’ if they presented with unresectable
and/or systemic (stage IV) disease at any time during follow-
up. Patients were scored as ‘‘non-progressors’’ if they
remained free of melanoma during the entire follow-up period
of at least 24 months (median time to censor 61 months).
Progression was selected as an end point rather than survival
to avoid bias introduced by subsequent treatments known to
prolong survival in the metastatic setting, whereas recurrence
per se was not selected as an end point because patients who
have an isolated resectable loco-regional recurrence remain at
relatively low risk of further progression (approximately 50%),
making the recurrence less clinically significant in these
patients (Francken et al., 2008).
On the basis of these criteria, an initial training set of 47
patients was identified. RNA of sufficient quality for Nano-
String analysis was obtained in 40 of these cases (85%, see
Materials and Methods). Heat map depicts mRNA copy
number using unsupervised clustering in the 40 patients
(Figure 1c). As shown, the distribution of samples is nonran-
dom with higher expression of immune genes in patients who
did not progress.
Identification of a 53-gene immune panel predictive of
non-progression, RFS, and DSS in the training set
Each one of the 446 candidate genes was assessed for its
ability to distinguish between progressors and non-progressors
using two standard classification methods: random forest and
elastic net. A subset of 53 genes was selected as the final gene
panel (Figure 2a). Receiver operating characteristic curves
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were generated using fivefold cross-validation on the training
set with a mean area under the curve of 0.920 (Figure 2b). Ten
thousand training data sets were then generated by randomly
removing eight bootstrapped samples of the data. The
removed samples served as the testing data sets. Receiver
operating characteristic curves were generated and the dis-
tribution of AUCs is shown in Figure 2c. Interestingly, all 53
genes were upregulated in the non-progressors, a bias that
significantly deviates from what we would expect by chance
(Po0.001).
Next, the gene signature was evaluated in the context of
known clinically relevant predictors. Stage (P¼0.027), depth
(P¼ 0.033), and age (P¼ 0.014) significantly correlated with
progression by logistic regression, whereas ulceration and
mitotic rate trended toward significance (P¼0.053 and
P¼0.062, respectively). TILs, gender, and location of the
primary tumor did not significantly correlate with progression.
Multivariate logistic regression showed that the 53-gene
signature score was the best predictor of progression
(Po0.001), with the gene signature contributing significantly
to the accuracy in the context of known predictors (Po0.001).
The 53-gene signature was then tested as a predictor of both
RFS and DSS using Cox analysis and correlated with both end
points (Po0.001) in a univariate model. The 53 genes were
lastly examined in the context of known clinical predictors.
TILs, mitotic rate, depth, age, and location on an extremity
correlated with DSS. Ulceration and stage III disease trended
toward significant correlation with diminished DSS (P¼ 0.060
and P¼ 0.072, respectively). In multivariable analysis, the
gene signature added significantly to the predictive power of
clinicopathologic features for both RFS and DSS (Po0.001).
Identification of a closely related immune module using
unbiased coexpression analysis of the GEO database
To further assess the applicability of our findings to melanoma
patients, and to define key node genes driving the immune
Immune gene with proposed impact on
melanoma progression:
294
Immune gene with proposed
impact on cancer progression:
96
Total number of
candidate genes:
446
Relative mRNA expression
0.0 –3.0+3.0
Non-progressor Progressor
Non-immune gene with proposed
impact on melanoma progression:
29
Characteristics of the traning set
Characteristics
Clinical characteristics
Gender
Male, no. (%) 28 (70)
12 (30)
67 (29–87)
24 (60)
16 (40)
18 (45)
22 (55)
2.65 (1.2–13)
21 (52)
19 (48)
7 (17)
28 (70)
5 (13)
6.5 (0–26)
21 (52)
17 (43)
19 (6–81)
61 (25–130)
Female, no. (%)
Trunk, no. (%)
Extremity, no. (%)
II, no. (%)
III, no. (%)
Stage
Pathological characteristics
Depth (mm), median (range)*
Tumor-infiltrating lymphocytes
Patient outcome
Mitoses, median (range)
Disease progression, no. (%)
Died from melanoma, no. (%)
Patient follow-up (months)
Time to death, median (range)
Time to censoring, median(range)
* Depth is available for 39 patients.
Ulceration
Present, no. (%)
Absent, no. (%)
Absent, no. (%)
Non-brisk, no. (%)
Brisk, no. (%)
Age median (range), no.
Location of tumor
Training set (N =40)
Figure 1. In all, 446 immune-related genes were profiled using NanoString technology, and a subset of 53 genes predicts clinical non-progression in two
independent sets of patients. In (a), a diagram describes the schema for selection of the 446 genes. (b) The clinical characteristics of patients in the training
set. In (c), relative levels of mRNA expression for each sample are depicted according to the color scale shown, with each column representing a
different patient sample and each row representing one of the 446 genes. Unsupervised hierarchical clustering was performed on both genes and samples.
Patients who progressed are labeled in blue and those who did not are labeled in yellow. Blue indicates higher expression and yellow indicates lower expression
of each gene in the color scale.
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signature, a coexpression network, consisting of 16,745 genes,
(Figure 3a) was reconstructed using data from 46 primary
melanoma patients (GEO accession ID: GSE15605)26. A 758-
gene module (highlighted in yellow in Figure 3a) was found to
be the most enriched for both the 53-gene panel and the 446-
gene panel. In all, 42 genes were found within the 758-gene
module, yielding an enrichment fold of 17.50 with a P-value
o2.2e-16. An enrichment fold was similarly computed for the
same module against the 446-gene panel where 161 genes
were found in the 758-gene module, yielding an enrichment
fold of 7.98 with P-value o2.2e-16. The enrichment fold
increased over twofold in the more refined set of genes, which
indicates a higher correlation among the selected 53 genes
compared with the original 446 genes. These data show that
the 53-gene panel is closely related to a coexpression module
discovered by unbiased network analysis of the GEO database
as 42 genes from the panel were found within the 758-gene
module. In fact, these 42 genes correlated closely with
progression in the training set showing that they contain a
significant fraction of the predictive power of the original
53-gene panel (Supplementary Figure S2 online).
Bayesian network shows high connectivity among the 53 genes
in the immune panel
To further illustrate the causal regulatory mechanism of
immune response, interactions within and around the 53-gene
panel were investigated. A neighborhood of genes related to
the 53-gene panel was first selected using the knowledge base
network tool VisAnt (see Supplementary Methods page 9 online).
A Bayesian network was constructed for the VisAnt gene list
(which includes the original 53-gene panel) using the mela-
noma gene expression data set (GSE15605) shown in Figure 3b.
A reference Bayesian network was similarly constructed for the
446-gene panel and its neighborhood set (Figure 3c).
Descriptive statistics across each Bayesian network (number
of interactions, clustering coefficients, density, and so on) are
listed below (Figure 3d). The 53-gene panel Bayesian network
is more densely connected with a 4.815-fold change relative
AUC
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Figure 2. RNA was extracted from 40 FFPE stage II–III primary melanoma specimens, and 53 genes predictive of melanoma progression were identified using
elastic net and random forest classifiers. See Supplementary Figure S1 online for gene selection method. In (a), a bar graph depicts the number of times
each of the 53 genes was selected using a leave-8-out cross-validation with bootstrapping. In (b), a mean receiver operating characteristic curve with
fivefold cross-validation to predict melanoma progression is shown, mean area under the curve (AUC)¼ 0.92, Po0.001. In (c), distribution of AUC values
using a leave-8-out cross-validation with bootstrapping test is shown.
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to the 446-gene panel Bayesian network. Similarly, the
clustering coefficients (both global and local) are over twofold
change relative to the 446-gene panel Bayesian network.
Therefore, a significant improvement in the connectivity was
observed in the 53-gene panel of predictive genes, possibly
indicating a more significant biological mechanism.
Bayesian network identifies driver genes with immune-
surveillance function
To identify potentially significant driver genes, genes were
ranked by their out-degree. The top 25 hub genes in the
53-gene Bayesian network are listed with functional annotation
in Supplementary Table S3 online. Hub genes are expressed by
infiltrating immune cells implicated in immune surveillance,
including CCR5 (Th1 response), CD8a, CD8b, CD3, and IKZF1.
Interestingly, the 42-gene subset of our 53 marker genes shows
a significantly higher number of regulatory interactions in the
immune nodule from the GEO network relative to the other
genes (marker genes are indicated by blue nodes in Figure 3b).
Interaction network and coexpression network pathway
enrichment analyses
Next, we tested which functional pathways were enriched in
our 53-gene panel. The gene list generated by VisAnt, which
was later used to construct the Bayesian network, was
annotated with Pathway and GO molecular function (full
table of results for the 446-gene panel network and 53-gene
panel network are in Supplementary Data set S1 online). The
top 10 most significant enriched pathways or GO terms are
shown in Supplementary Table S4 online for the 446-gene
panel network genes and the 53-gene panel network genes,
respectively. Interestingly, we see that the smaller network
surrounding the 53 genes shows a higher enrichment of
biological processes that characterize lymphocyte function
and immune surveillance. Moreover, the enrichment fold
change (Supplementary Table S4 online) in the top enriched
terms for the 53-gene panel network ranges from 5- to 11-fold,
whereas the enrichment fold change of the top 10 terms
corresponding to the 446-gene panel network (Supplementary
Table S4 online) ranges from just 2- to 4-fold. Therefore, a
higher functional enrichment was observed in the network
induced by the 53-gene panel.
Finally, we sought to determine whether the module
identified in GEO correlated functionally with our proposed
53-gene signature. The functional pathways enriched by the
yellow module derived from the GEO model (Figure 3c) are
listed in Supplementary Data set S1 online. The top 10 enrich-
ment terms for the GEO module are listed in Supplementary
Table S4 online and enriched for immune response. These
findings show that a module enriched for immune processes
known to be implicated in immune surveillance is identified
both in two independent melanoma patient populations of
matched stage and also in primary melanoma data from GEO.
Confirmation of the 53-gene immune panel in a second test set
of 48 stage II–III primary FFPE melanomas for progression, RFS,
and DSS
Given the number of genes in the above analysis and the
moderate number of samples comprising the test set, there is a
danger of over-fitting the classifiers (an overdetermined
system) even with statistical procedures such as cross-valida-
tion. Therefore, we assembled the independent test set to
replicate our classification results from the test set. In all, 57
patients were identified using identical criteria to the training
set, with an additional participating institution (NYU), and
RNA was successfully extracted from 48 melanomas (84%).
The clinical characteristics of the test population are shown
in table, Figure 4a and were generally similar to the training
set with the exception of mitotic rate (Supplementary Table S5
online). Logistic regression showed that ulceration (P¼ 0.013)
Genes
(nodes)
37753-Gene panel network
446-Gene panel network
Fold change
2,259
1,187
10,014
8.37E-3
1.96E-3
4.26 2.13
Average
local CCDensity
Interactions
(edges)
Local
CC SE
Average local CC
P -value
Global ICC
P -valueGlobal ICC
0.0756
0.0355
8.34E-3
1.57E-3
0
0
0
0
2.04
0.0811
0.0397
Figure 3. Immune response Bayesian network surrounding the 53-gene panel and the 446-gene panel networks. Larger node size indicates larger edge
degrees. The 53-gene panel (dark blue) in (a) forms a denser network of gene–protein or protein–protein interactions (green) with neighbor genes (pink)
than the network surrounding the 446-gene panel as shown in b. (c) Coexpression network on 46 gene expression profiles in primary melanoma patients.
The yellow dots compose a 758-gene module within the entire gene genome (pink). Red lines denote interactions between nodes, involving nodes within the
module. (d) Network attributes of the 53-gene panel and 446-gene panel networks. CC, clustering coefficient.
S Sivendran et al.
Immune Gene Networks and Antitumor Surveillance
2206 Journal of Investigative Dermatology (2014), Volume 134
and depth (P¼0.044) associated significantly with progression
in the test set. Death rates were 43% and 36% in the training
and test populations, respectively, generally consistent with
the expected death rates based on American Joint Committee
on Cancer staging over the follow-up time (median 61 months
in the training set and 53 months in the test set).
We next examined the 53-gene panel in the test set as
shown in Figure 4b. A similar pattern of high immune gene
expression was observed in non-progressors as in the training
set (Figure 1c). Further, the 53-gene signature was able to
predict progression in the test set with an area under the curve
of 0.787 (Po0.001, Figure 4c). Cross-validation demonstrated
that this signature is statistically robust (Figure 4d). When the
53-gene panel was evaluated in the test set in the context of
clinicopathologic predictors, multivariate logistic regression
demonstrated that the gene signature remained predictive of
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Depth (mm), median (range)
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Tumor-infiltrating lymphocytes*
Patient outcome
Mitoses, median (range)*
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Time to censoring, median (range)
Patient follow-up (months)
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Figure 4. The 53-gene panel was tested using a second independent set of patients. The clinical characteristics of patients in the test set are shown in (a).
In (b), relative levels of mRNA expression for each sample are depicted according to the color scale shown, receiver operating characteristic curve to
predict melanoma progression is shown in (c), area under the curve (AUC)¼ 0.787, Po0.001. In (d), distribution of AUC values using a leave-4-out
cross-validation test is shown. In (e), Kaplan–Meier curves of survival based on a 21-gene signature and ulceration using a log-rank Mantel–Cox test are
shown for test set. Patients with negative gene signature and an ulcerated tumor had significantly diminished survival (P¼ 0.030). TILs, tumor-infiltrating
lymphocytes.
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progression (Po0.001). Ulceration was the only feature that
added significantly to the predictive power of the signature
(P¼ 0.035).
The 53-gene signature was then examined in terms of RFS
and DFS using Cox proportional hazards analysis in the test set
and correlated significantly with both (Po0.001 and
P¼0.024, respectively). No other clinical feature correlated
significantly with DSS in the test set of 48 patients with
median time to censor of 47 months, although ulceration
tended toward significance (P¼0.087). Multivariable analysis
showed that the best model to predict DSS within the test set
included gene signature and ulceration (P¼ 0.019). Ulceration
and an unfavorable immune signature identified a population
at high risk of death with a median survival of 49 months as
compared with 139 months in patients with one or none of
these risk factors (Figure 4e, P¼ 0.030). Thus, the immune
gene signature enhances the ability of established clinico-
pathologic features to predict progression and survival in a
second independent test population.
Validation of expression data at the protein level and
identification of CD2 as an immunohistochemical marker of
favorable prognosis
In order to validate mRNA data obtained by NanoString,
staining by immunohistochemistry (IHC) was performed.
Results were concordant with NanoString results as determined
by linear regression for CD2, the most differentially expressed
gene between progressors and non-progressors (r¼ 0.799;
Figure 5a and c). CD5 and CD4 staining by IHC also correlated
with the NanoString data (r¼ 0.666 and r¼0.543; Figure 5b
and d, respectively). Thus, immunohistochemistry correlated
with the mRNA results from NanoString.
CD2 was the most differentially expressed gene between
progressors and non-progressors within the training set (P¼
0.002). Frequency of CD2-positive cells by IHC correlated
strongly with melanoma non-progression in the combined
populations (Po0.001; Figure 5e). Thus, the NanoString
analysis allowed for the identification of a novel immunohis-
tochemical stain that may be predictive of outcomes in
patients with completely resected stage II–III melanoma.
DISCUSSION
In this work, we tested a candidate panel of 446 genes and
defined a proposed biomarker consisting of 53 immune genes
associated with non-progression, RFS, and DSS in a training
set of 40 patients with completely resected stage II–III mela-
noma. Next, we identified, using publicly available data and
unbiased methods, a module of 758 genes coregulated in
melanoma tissues including 42 genes out of the proposed 53-
gene panel. The fact that these 758 genes were coregulated,
meaning that their expression levels are coordinated across
multiple primary melanoma tumors, suggests related biologic
function. Bayesian analysis of this coexpression module
identified driver genes with key roles in lymphocyte aggrega-
tion and activation, including CCR5, CD8, CD3, and IZKF1,
showing that this module is related to T-cell activity, specifi-
cally the Th1 signaling pathways. Finally, the predictive value
of the proposed 53-gene signature was confirmed in a second
independent test set of 48 patients, and findings were
corroborated by IHC at the protein level with identification
of CD2 as a marker of non-progression. These findings should
lay the groundwork for the definition of immune biomarkers of
clinical utility in primary melanoma tumors on the basis of
larger prospective studies.
Notably, our work is consistent with the hypothesis that the
immune system is protective against cancer progression and
with the concept of the immunoscore proposed by Galon
et al. (Galon et al., 2013) whereby careful quantification of
immune infiltrates carries prognostic value in multiple tumor
types . Although traditional tumor staging focuses only on the
characteristics of the tumor, the immunoscore considers the
patient’s immune response and thus can provide a more
accurate prognosis. Our work is in primary tumors, and our
findings certainly do not exclude the possibility that tumors
evolve to co-opt the immune system and therefore immune
activity may be nefarious in more advanced melanomas. Also,
melanoma is not likely caused by a virus or other inflammatory
insult, and our findings would suggest that inflammation does
not abet the progression of most early-stage melanomas. It is
nonetheless striking that the immune genes are generally
upregulated in patients who did not progress. There are other
contributing features intrinsic to the tumor that affect
outcomes, as the clinical course is not likely entirely dictated
by the immune system. Thus, the ability of our 53-gene panel
to predict survival was improved in the test set by the inclusion
of ulceration, generally considered a marker of invasiveness.
Given the current excitement about immunotherapy in the
metastatic setting, sorting out which patients have a favorable
immune profile is likely to be useful for patient stratification
when agents such as anti-PD1 and anti-CTLA4 are tested in
the adjuvant setting. A recent report proposed a gene panel
predictive of response to a tumor vaccine (Kruit et al., 2013),
and it will be interesting to learn which pathways are
important to predict response to immunotherapy and how
these might relate to the prognostic immune surveillance
signature reported here.
Intriguingly, the functions of the genes at the top of the 53-
gene panel (Supplementary Table S3 online) focus on T-cell
and natural killer functions, as well as leukocyte migration.
Meanwhile, driver genes identified on the basis of the GEO
module have similar functions. This observation is formalized
through the enrichment analysis performed using DAVID
(Supplementary Data set S1 online). CD2, a costimulatory
molecule and a marker of activation, is expressed on T cells
and NK cells. The significance of CD2 is highlighted by the
fact that two CD2 ligands, CD53 and CD48, are also found in
the 53-gene panel. Other highly differentially expressed genes
between progressors and non-progressors include KLRK1 and
HLAE, ligands for each other and implicated in NK cell–
mediated immunosurveillance, as well as CD4, CD3, LCK,
and ITK, genes associated with TCR signaling. CCR5, top hub
gene, characterizes the Th1 response and is implicated in
leukocyte aggregation to sites of inflammation (Loetscher
et al., 1998). Key ligand for CCR5, CCL5, is also included in
the 53-gene panel. Other top driver genes, CD8a and CD3,
are markers for cytotoxic T-cell infiltration. IKZF1, meanwhile,
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is a regulator of transcription restricted to lymphocytes
and may mediate phenotypic changes important for anti-
melanoma immunity. There are many reasons why CD2
RNA levels may be more prognostic than CD8 levels, one of
them being that CD2 is a marker of activation, whereas CD8
expression is downregulated when T cells are activated. CD2
is also expressed by innate lymphocytes, cells that may have
important roles in immune surveillance. (See Supplementary
Table S3 online for a referenced list of hub gene functions and
corresponding NanoString expression data.)
In summary, we identify a 53-gene panel predictive of
melanoma progression in two independent cohorts. We find
that 42 of these genes are present in an immune subnetwork
found in the GEO database, and that driver genes in this
network have key roles in lymphocyte activation and recruit-
ment. This work is based on data gathered retrospectively on
the basis of chart reviews from three independent melanoma-
treatment centers and is therefore preliminary. However,
results presented here should be of practical utility in the
design of future large-scale studies to develop genomic
biomarkers of clinical relevance for adjuvant immunotherapy
studies. Clearly, evidence of immune activity with clinical
implications can be discovered in primary melanoma tumors.
Measuring expression of key immune genes in FFPE tissue
should be a promising way to make this information available
to researchers, clinicians, and patients.
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Figure 5. Immunohistochemistry (IHC) using anti-CD2 mAb was performed to assess risk of disease progression. (a) Photographs of a tumor expressing low levels
of CD2 from a progressor (left), and a tumor with high CD2 levels from a patient who remained disease free are shown (right). A brisk peritumoral infiltrate
is seen on hematoxylin and eosin (H&E) in the tumor that did not progress. Clockwise from top left, scale bar indicates 400mm, 200mm, 160mM (inset: 80mm),
and 200mm (inset: 80mm). A linear regression model is used to assess correlation in Nanostring with IHC for CD5 (b), CD2 (c), and CD4 (d) in the training set.
(e) The average number of CD2-positive cells counted at 40x magnification in eight random HPFs in the training and test sets is shown (Po0.0001).
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MATERIALS AND METHODS
Patients and samples
This study was approved by the Institutional Review Boards, and
patients provided written informed consent when required. The
investigation was conducted according to the Declaration of
Helsinki Principles. The training set included FFPE primary mela-
noma tumors from 40 patients with completely resected stage II–III
melanoma identified by screening dermatopathology databases
between January 2001 and January of 2011 at GMC (32 patients)
and MSSM (8 patients). Authorized personnel obtained clinical
information at each institution. Patients with incomplete clinical
follow-up in the medical record were contacted by mail and
telephone under an IRB-approved protocol and included if ade-
quate follow-up was obtained. The test set included additional
patients from the GMC (16 patients), MSSM (7 patients), and New
York University Medical Center (New York, NY, 25 patients). A
complete review of all patient records was performed on December
31, 2011 for the training set and December 31, 2012 for the test set.
Data prepared at all three centers were reviewed centrally at MSSM
to determine whether patients had recurred, progressed to unre-
sectable stage III or stage IV, or had died, and all living patients
were censored on this date or the most recent preceding date of
available follow-up.
Analysis of gene expression
RNA was extracted from primary melanoma specimens using the
Ambion RecoverAll Total Nucleic Acid Isolation Kit (Life Technologies,
Carlsbad, CA, Supplementary Methods page 3 online). A concentra-
tion of RNA of at least 20 ng ml 1 and a detectable peak on the
tracing at 50 bp or above was required for NanoSrting analysis. A total
of 446 genes were selected on the basis of a PubMed literature review
(Figure 1a and Supplementary Tables S1 and S2 online). The nCounter
platform (NanoString Technologies, Seattle, WA) was used to quantify
relative mRNA copy number (Supplementary Methods page 4 online;
Geiss et al., 2008).
Immunohistochemistry
IHC was performed on 5-mm charged slides using anti-CD2 mAb
(MRQ-11, Ventana Medical Systems, Tucson, AZ). Sections were
deparaffinized and stained using a Ventana BenchMark XT immu-
nostainer. Slides were evaluated by two of the study authors (SGB &
MMM) in a blinded manner in eight random high powered fields
using an ocular micrometer with a 1 mm2 grid (Nikon Eclipse E40,
Tokyo, Japan).
Ensemble classification/regression method and receiver
operating characteristic curves
Classification was performed using an ensemble feature selection
method encapsulating two standard classifiers: random forest and
elastic net, both embedded in data bootstrapping to boost the
robustness of the final gene panel. The starting 446 genes from the
training experiment were ranked and filtered based on prediction
power of melanoma progression in the training cohort, and a subset
of 53 genes was selected as a final gene panel. Receiver operating
characteristic curves were generated and the area under the curve
was calculated on both training and test data sets. Detailed methods
are included in the Supplementary appendix online page 6 and in
Supplementary Figure S1 online.
Demographic, survival, and multivariable analysis
The two-tailed student’s t-tests generated P-values for continuous
variables including age, depth, and mitotic rate. Other noncontinuous
characteristics were analyzed using the two-tailed Fisher’s exact test
or, in the case of TILs, a w2-test. Graphpad Prism version 5.0
(GraphPad Software, La Jolla, CA) was used (San Diego, CA) and
statistical significance was defined as Po0.05 without correction for
multiple comparisons. For RFS and DSS analysis, Kaplan–Meier
analysis and log-rank (Mantel–Cox) tests were performed. Standard
multivariable logistic and Cox proportional hazards analysis were
performed using XLSTAT (Addinsoft, Brooklyn, NY) software.
Coexpression and gene network analysis
From the NIH GEO database, 46 samples of gene expression data
identified on the basis of origin in primary melanoma tissue and
expression platform (Supplementary Table S6 online) were collected
(GEO accession ID: GSE15605)26. Coexpression network analysis
was performed using Weighted Gene Coexpression Network Analysis
(WGCNA)27 to identify highly correlated gene modules among
whole-genome genes in early-stage melanoma patients. To construct
a network around the 53-gene panel, a biologically relevant gene set
surrounding the 53-gene panel was obtained using the knowledge
base tool using VisAnt28,29 (for full details see Supplementary
Methods page 9 online).
Pathway and gene ontology enrichment
Gene panels were annotated using the functional database and tool
DAVID.30,31 The default list of whole genome was the background
set, and each network list was tested for enrichment of the KEGG
pathways, or GO term biological process, or GO term molecular
function (MF).
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